Aquestive Therapeutics Inc. (AQST)
NASDAQ
Aquestive Therapeutics Inc. EBITDA 2017–2025
Aquestive Therapeutics Inc. annual/quarterly ebitda history and growth rate from 2017 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Aquestive Therapeutics Inc. ebitda for the quarter ending March 31, 2026 was -4.1 M, a 78.72% decrease year-over-year.
- Aquestive Therapeutics Inc. ebitda for the twelve months ending March 31, 2026 was -36.3 M, a 13.55% decrease year-over-year.
- Aquestive Therapeutics Inc. annual ebitda for 2025 was -70.5 M, a 134.60% increase from 2024.
- Aquestive Therapeutics Inc. annual ebitda for 2024 was -30.1 M, a 118.46% increase from 2023.
- Aquestive Therapeutics Inc. annual ebitda for 2023 was -13.8 M, a 65.33% decrease from 2022.
- Aquestive Therapeutics Inc. annual ebitda for 2022 was -39.7 M.
EBITDA
TRAILING 12 MONTHS · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Aquestive Therapeutics Inc. EBITDA — FAQ
Aquestive Therapeutics Inc. (AQST) ebitda over the last 9 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see AQST's ebitda history?
The chart and table above show Aquestive Therapeutics Inc.'s ebitda by year and by quarter, including the growth rate.